Synthesis, biological evaluation, and utility of fluorescent ligands targeting the μ-opioid receptor by Schembri, Luke S. et al.
Schembri, Luke S. and Stoddart, Leigh A. and Briddon, 
Stephen J. and Kellam, Barrie and Canals, Meritxell and 
Graham, Bim and Scammells, Peter J. (2015) Synthesis, 
biological evaluation, and utility of fluorescent ligands 
targeting the μ-opioid receptor. Journal of Medicinal 
Chemistry, 58 (24). pp. 9754-9767. ISSN 1520-4804 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/50604/1/Schembri
%202015%20JMedChem_Manuscript_Accepted.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
1 
Synthesis, Biological Evaluation and Utility of Fluorescent 
Ligands Targeting the µ-Opioid Receptor 
 
Luke S. Schembri,† Leigh A. Stoddart,§ Stephen J. Briddon,§ Barrie Kellam,‡               
Meritxell Canals,‡  Bim Graham,*,† and Peter J. Scammells*,† 
 
† Medicinal Chemistry and ‡ Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 
Monash University, Parkville, Victoria, 3052, Australia. 
§  Cell Signaling Research Group, School of Life Sciences, Queen’s Medical Centre, University of 
Nottingham, Nottingham NG7 2UH, UK  
‡ School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 
2RD, UK 
 
KEYWORDS: opioid receptor, fluorescent imaging, opioid antagonist, fluorescent ligand 
  
  
2 
ABSTRACT:  Fluorescently-labeled ligands are useful pharmacological research tools for studying 
receptor localization, trafficking and signaling processes via fluorescence imaging. They are also 
employed in fluorescent binding assays.  This study is centered on the design, synthesis and 
pharmacological evaluation of fluorescent probes for the opioid receptors, for which relatively few 
non-peptidic fluorescent probes currently exist.  The known µ-opioid receptor (MOR) partial agonist, 
buprenorphine, was structurally elaborated to include an amidoalkylamine linker moiety that was 
coupled with a range of fluorophores to afford new fluorescent probes.  All compounds proved to be 
selective MOR antagonists.  Confocal fluorescence microscopy studies revealed that the probe 
incorporating a sulfonated cyanine-5 fluorophore (3) was the most appropriate for imaging studies.  
This ligand was subsequently employed in an automated fluorescence-based competition binding assay, 
allowing the pKi values of several well-known opioid ligands to be determined.  Thus, this new probe 
will prove useful in future studies of MOR receptor pharmacology. 
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 INTRODUCTION  
 Opiates, such as morphine, are one of the most efficacious classes of analgesics in use today for 
the treatment of acute and chronic pain.  They elicit their effects by binding to the three “classical” 
opioid receptors (ORs) – the μ, κ and δ receptors (MOR, KOR and DOR) – and some to the more 
recently discovered nociceptin receptor (NOR),1,2 all of which are classified as class A, peptide-
binding, -subtype G protein-coupled receptors (GPCRs).3 The four ORs couple to the same major 
intracellular signaling pathways, interacting with G proteins of the Gi/o family.  Upon GPCR activation, 
the β/subunit of the heterotrimeric G protein is released and acts to inhibit voltage-gated calcium 
channels and activate inwardly-rectifying potassium channels.  This in turn leads to cell 
hyperpolarization and inhibition of neurotransmitter release, thus inhibiting neuronal signaling.4  
Additionally, the  subunit of the G protein inhibits adenylyl cyclase and hence decreases intracellular 
cyclic adenosine monophosphate (cAMP) production.5,6 
 Notwithstanding their effectiveness as analgesics, opiates suffer from a myriad of dose-limiting 
side-effects, including constipation, hallucinations, sedation, respiratory depression and, perhaps most 
significantly, tolerance and physical dependence.7 In order to develop opiates with an improved side-
effect profile, more fundamental biological research is needed to determine how such adverse effects 
arise.  Additionally, more structure-activity relationships (SARs) must be established so as to be able to 
enhance or maintain potency whilst reducing or eliminating undesirable side-effects.   
 Fluorescently-labeled GPCR ligands are useful for the above endeavors as they can be used in an 
array of pharmacological experiments, most notably, real-time monitoring of cellular processes such as 
receptor trafficking and ligand binding.8–13  Due to their high sensitivity, such probes can generate 
meaningful pharmacological data from a few cells (such as a biopsy) and thus may be useful in 
determining pharmacological differences between diseased and healthy tissue.  Moreover, they may be 
used to determine the binding affinity of drug candidates via fluorescence resonance energy transfer 
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(FRET)-based assays or assays involving displacement of a probe containing an environmentally-
sensitive fluorophore.14   
 Traditionally, receptor binding assays have been performed using competitive radioligands, with 
the binding affinity of a drug candidate determined from its ability to displace a high-affinity 
radiolabeled ligand.  Such experiments require a large population of cells, whereas information can be 
obtained from just a few cells, or even a single cell, using fluorescent probe-based experiments.15  
Fluorescent probes are generally easier to handle, provide high sensitivity, and can be used to visually 
differentiate between specific and nonspecific binding if used in conjunction with fluorescently labeled 
receptors.16  Moreover, from a safety point of view, the waste generated from the use of such probes is 
far less dangerous to the environment and the user than that produced by radiometric assays,17 making 
them more amenable to high-throughput screening (HTS) applications.  A fluorescent ligand must, 
however, be carefully designed to ensure that it retains (or improves upon) the pharmacological 
properties of the ligand upon which it is based.  Due consideration must be given to not only the choice 
of ligand, but also linker length, linker chemistry, site of linker attachment, as well as the 
fluorophore.14,15 
 Relatively few fluorescent probes have been developed thus far for the ORs.  Fluorescently-
labeled enkephalin peptides (endogenous OR ligands) were the first such compounds to be reported.18–
23.  Artamangkul, Macey and coworkers appended the Alexa 488 and 594 fluorophores to dermorphin 
and employed these conjugates in various imaging and receptor trafficking studies.10,11,13  Most 
recently, Ghosh and co-workers decorated fluorescent quantum dots with multiple copies of a 
Deltorphin-II analog peptide, permitting single-molecule imaging of the human DOR expressed in 
CHO cells.24  In terms of non-peptidic designs, Kolb et al.25 have labeled oxymorphone, naltrexone and 
naloxone at the C-6 position with fluorescein (and rhodamine-B in the case of naloxone).  Although the 
resulting probes broadly retain the OR-mediated activities of their parent compounds, their receptor 
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binding affinities were significantly diminished, and they were not employed for fluorescent 
visualization/detection of ORs.25  Medzihradsky, Emmerson and co-workers have attached the 
environmentally-sensitive (solvatochromic) fluorophore, 7-nitrobenzo-2-oxa-1,3-diazole (NBD), to a 
tetrahydrothebaine derivative,26 and both NBD and the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
(BODIPY) fluorophore to -naltrexamine.26,27  TheNBD-bearing compounds lacked significant 
selectivity, and the absorbance and emission wavelengths of the NBD and green-emitting BODIPY 
fluorophores are not optimal for biological imaging applications.  The tetrahydrothebaine derivative 
was also too hydrophobic, leading to non-specific binding to cellular membranes.26  The BODIPY 
derivatives exhibited MOR affinities in the nanomolar-to-sub-nanomolar range, with one showing a 
selectivity ratio of > 40 for MOR over DOR and KOR.  Portoghese and co-workers have reported the 
development of fluorescein-labeled KOR-selective arylacetamide agonists,28 however fluorescein 
suffers from a high photo-bleaching rate29 and its photophysical properties are generally not optimal for 
receptor imaging studies. 
 It is clear from the above that there still remains considerable scope for the development of 
fluorescent OR probes of practical utility, i.e., probes possessing both binding and photophysical 
properties suitable for imaging of OR localization and trafficking, and/or fluorescent-based screening 
assays. Herein, we present the synthesis, biological evaluation and application of a series of fluorescent 
OR antagonists with improved MOR selectivity (Figure 1), based on the high-affinity opioid, 
buprenorphine.  The latter is indicated in Europe for the relief of pain, whilst globally it is used in the 
treatment of opiate abuse. It is a partial MOR and NOR agonist, KOR and DOR antagonist, is more 
potent than morphine, and has less unwanted side-effects owing to its ceiling effect on tolerance and 
respiratory depression.30  It provides an attractive scaffold for generating fluorescent probes for ORs 
because of its strong binding affinity [pKi (MOR) = 8.8]
31 and the possibility to couple it to certain 
chemical moieties, such as a spacer or linker.  Indeed, some related compounds already have alkyl 
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chains appended at the C-20 position and this has resulted in extremely high affinity ligands.32  Inspired 
by this work, probes were designed featuring four different fluorophores: sulfonated cyanine-5 (sulfo-
Cy5), boron dipyrromethene difluoride (BODIPYTM) 630/650, 4-((6-methoxy-1,2,4,5-tetrazin-3-
yl)oxy)butanoic acid (tetrazine) and 3-(6-amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-
yl)propanoic acid (naphthalimide).  Through measurement of their respective receptor pharmacology, 
alongside fluorescence confocal microscopy, this study clearly demonstrates the suitability of the sulfo-
Cy5-bearing fluorescent ligand, in particular, for receptor localization studies, as well as in vitro 
binding assays. This probe possesses the advantage of exhibiting increased fluorescence in the MOR-
bound state, obviating the need for a wash step included in many competitive binding assays.   
 
 
 
Figure 1.  Structures of fluorescent OR ligands synthesized in this study. 
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 RESULTS AND DISCUSSION  
 Fluorescent ligand design and synthesis.  A range of ligand design options were considered in 
which the linker and fluorophore could be attached to different positions of a morphinan core.  Linking 
from the tertiary amine seemed chemically feasible (e.g. via N-demethylation and alkylation), however 
the OR crystal structures1,7-9 suggested that this amine is buried deep within the active site and would 
therefore have limited tolerance to groups appended at this position.  Some substitutions at this position 
can convert agonists to antagonists, as evidenced by naltrexone. Linking from the 3-position of the 
phenol moiety was another potential strategy.  However, even simple methylation at this position 
(codeine) reduces binding affinity by approximately 200-fold.33  A more interesting possibility for 
linker attachment was the 7-position of the morphinan scaffold, via a Diels-Alder reaction, since this 
could lead to an increase in affinity, as demonstrated by ligands such as etorphine and buprenorphine.34  
Previous work conducted on the development of fluorescently labeled OR ligands25–28 as well as 
bivalent ligands35–44 indicates that the C-ring of the morphinan scaffold (which incorporates the 6- and 
7-positions) is generally reasonably tolerant of substitution.  With these factors in mind, the synthesis 
and biological evaluation of three different congeners (Figure 2) featuring a linker attached via the 7-
position were pursued.  In two of these structures (9 and 11) the linker was attached via a Diels-Alder 
reaction involving the C-ring diene of oripavine and methyl acrylate. Subsequent saponification and 
amide coupling incorporated the full linker unit (amide congeners).  The third congener was derived 
from the Diels-Alder reaction of oripavine with a fully formed linker unit that possessed a terminal N-
substituted maleimide group (imide congener).  Literature precedence suggests that conjugation of a 
maleimide group retains affinity when connected in this position, and alkyl chains are also 
tolerated.45,46   
 
  
8 
  
Figure 2.  Structures of buprenorphine-like congeners prepared in this study. 
 
 Amide congeners.  Scheme 1 details the synthetic pathway used to access the amide derivatives, 
with oripavine as the starting molecule.  Following protection of phenol 5 to its corresponding tert-
butyldimethylsilyl (TBS) ether (6), a Diels-Alder reaction between the latter and methyl acrylate, 
afforded ester 7.47  Compared to dienophiles such as methyl vinyl ketone, the ester presents a weaker 
electron-withdrawing group compared to the ketone, therefore requiring more forcing conditions to 
achieve complete conversion to the Diels-Alder product.  This was achieved through irradiating the 
sample for three hours at 130 oC in a microwave in neat methyl acrylate.  Compound 7 was isolated in 
good yield (69%) following recrystallization from minimal hot methanol, which was necessary to 
remove a small amount of the 8-regioisomer byproduct. 
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Scheme 1.  Synthesis of amide congeners.a 
  
a Reagents and conditions: (a) TBSCl, imidazole, DMF, RT, 1 min, 94%; (b) methyl acrylate, µW, 130 
oC, 3 h, 69%;  (c) i. 1 M LiOH, THF (1:1), RT, 14 h; ii. EDC.HCl, HOBt, DIPEA, DMF, N2, RT, 14 h, 
44%; (d) 10% Pd/C, H2, RT, 10 bar, 2 h, 86%; (e) 4 M HCl, RT, 30 min, 39% for 9, 29% (over two step 
from 8) for 11. 
 
 Saponification of methyl ester 7 with lithium hydroxide and subsequent amide coupling with tert-
butyl (6-aminohexyl)carbamate using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC.HCl) and N-hydroxybenzotriazole (HOBt) afforded Boc-protected congener 8 in a respectable 
yield (44%) with > 95% purity according to HPLC.  An “H-cube” hydrogenation system was then 
employed to reduce the olefin in the next step (small scales of 500 mg or less).  This occurred cleanly 
within two hours to produce 10 in high yield (86%).  Acidolytic Boc group removal was performed on 
both the unreduced (8) and reduced (10) versions of the protected congeners to give compounds 9 and 
11 respectively, as their bis-HCl salts following lyophilization. 
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 Imide congener.  The synthetic route for these derivatives commenced with synthesis of a 
maleimide-bearing linker group though reaction of N-(ethoxycarbonyl)maleimide48 with mono-Boc-
protected diaminohexane (Scheme 2).  After one hour, 12 was obtained as a pure white solid in high 
yield (89%).  This high yield was only achieved if fresh (no more than a week old) N-
(ethoxycarbonyl)maleimide was used and if the amine was stirred in saturated NaHCO3 at 0 
oC before 
adding in the maleimide. 
 
Scheme 2.  Synthesis of the imide congener.a   
 
a Reagents and conditions: (a) i. 3:5 THF/sat. NaHCO3 (aq), 0 
oC, 15 min; ii. 3:17 (v/v) THF/sat. 
NaHCO3 (aq), RT, 45 min, 89%; (b) EtOH, reflux, 5 h, 52%; (c) 4 M HCl, RT, 30 min, 86%. 
 
 Compound 13 was synthesized via a Diels-Alder reaction between 12 and oripavine (Scheme 2).  
This reaction required less forcing conditions compared to methyl acrylate as the maleimide group is a 
stronger dienophile.  Additionally, as the maleimide is connected through both the 7 and 8 positions, no 
minor regioisomer byproducts were produced and hence purification was performed via silica 
chromatography. 
 Unfortunately, reducing the alkene moiety of these compounds proved problematic.  Reaction 
conditions trialed in the H-cube included pressures as high as 20 bar (280 psi), yet no reduction took 
place, even after two hours.  One possible explanation for this difficulty is that the bulkiness of the 
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maleimide group hinders the olefin’s approach to the palladium catalyst.  Only the unreduced version 
of this congener was therefore tested, and it was assumed that enough information about the effect of 
the olefin on potency and affinity could be garnered from the amide congeners.  Finally, acidolytic 
removal of the Boc protecting group of 13, followed by column chromatography to remove minor 
impurities, afforded congener 14 as its bis-HCl salt.  
 The different congeners were compared pharmacologically to assess which modifications were 
tolerated by the MOR and which, if any, retained the partial MOR selectivity of the parent molecule 
(vide infra).  In all cases, the corresponding tert-butyloxycarbonyl (BOC) protected congeners were 
also evaluated in order to help assess if there was potential receptor tolerance for further chemical 
elaboration at the end of the linker unit. 
 Fluorescent ligands synthesis. The four fluorophores chosen for incorporation into our probes 
were BODIPYTM 630/650, naphthalimide, sulfo-Cy5 and tetrazine.  The necessary precursors were 
commercially available (BODIPYTM 630/650 SE) or readily accessed by literature procedures (sulfo-
Cy5 with a hexanoic acid pendant49 and 3-(4-amino-1,8-naphthalimido)propanoic acid50) for all but the 
tetrazine probe. Preparation of the later required the synthesis of a novel conjugatable tetrazine 
derivative (19) from 3,6-dichlorotetrazine (15)51 according to Scheme 3. Compound 18 features a 
butanoic acid linker at one end and a methoxy “cap” at the other.  Such alkoxy groups render tetrazines 
fluorescent.51–54  Additionally, these groups ensure that no other group reacts with the tetrazine via 
nucleophilic substitution, in particular thiols and amines, which cause loss of tetrazine fluorescence.51   
 Compound 15 was first reacted with excess methanol to replace one of the chloro groups with a 
methoxy substituent.54 Following this, the remaining chloro group was substituted with 1,4-butanediol 
in low yield (19%) by adapting the method of Gong et al.53 and employing NaH to deprotonate the 
alcohol reactant (substitution with 4-hydroxybutanoic acid was also trialed in an attempt to directly 
access 18, however this led to degradation of the tetrazine core). The low yield of 17 is thought to be 
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due to partial degradation of the tetrazine by the reactive alkoxide, combined with the formation of 
byproducts resulting from 1,4-butanediol displacing both the methoxy and chloro groups of 16 or 
forming crosslinked species (an extra equivalent of the diol was added in an attempt to minimize 
double-deprotonation of the diol). The penultimate step involved oxidation of the terminal alcohol 
under mild conditions, employing a catalytic amount of chromium trioxide (1.2 mol%) and periodic 
acid as per the method of Zhao et al.55 Finally, the carboxylic acid group of 18 was converted to the N-
hydroxysuccinimide (NHS) ester using dicyclohexylcarbodiimide (DCC) as the coupling reagent. 1H 
NMR analysis showed that the isolated sample of 19 contained dicyclohexylurea (DCU, 25% by mass 
according to 1H NMR), however it was considered adequate for the subsequent coupling step. 
 
Scheme 3. Synthesis of the conjugatable tetrazine fluorophore.a 
 
a Reagents and conditions: (a) MeOH, RT, 1 h, 82%; (b) i. NaH, 1,4-butanediol, dry THF, N2, RT, 30 min; 
ii. N2, dry THF, -78 
oC, 1 h; iii. RT, 1 h, 19%; (c) i. CrO3, H5IO6, ACN, 0 
oC, 30 min; ii. RT, 30 min, 
100%; (d) i. DCC, NHS, DCM, 0 oC, 1 h; ii. RT, 1 h, 97% recovery (75% 19, 25% DCU by mass). 
 
 The final step was to conjugate the fluorophores as per Scheme 4.  The amide congener 11 was 
selected over the imide congener due to its higher binding affinity (vide infra) (note that the bis-TFA 
salt form of 11 (11b), rather than the bis-HCl salt (11a), was used for three of the probes).  While 
BODIPYTM 630/650 and the tetrazine derivative were reacted as N-hydroxysuccinimide esters, 2-(6-
  
13 
chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) was used to 
couple the unactivated naphthalimide and sulfo-Cy5 derivatives to the congener.  The naphthalimide 
probe 1 was isolated in reasonable yield (48%) via this method, however a guanidiunium byproduct 
was detected in significant amounts for the sulfo-Cy5 probe 3, formed as a result of the amine reacting 
directly with the coupling reagent.56  The use of benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) as a coupling agent eliminated this problem, although 3 could still only 
be isolated in low yield (18%).  
 Conjugation of the BODIPYTM 630/650 and tetrazine fluorophores was performed using the 
reaction conditions set out by Middleton et al.57  Purification of 2 required only preparative HPLC 
(32% yield), however for 4, an extra extraction step (1:3 IPA:CHCl3) was required to remove the DCU 
carried over from the previous step (18% yield). 
 
Scheme 4. Synthesis of fluorescent OR ligands.a 
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a Reagents and conditions: (1) HCTU, DIPEA, N2, dry DMF, 2 h, RT, 48%; (2) DIPEA, N2, dry DMF, 
4 h, RT, 32%; (3) PyBOP, DIPEA, N2, dry DMF, 1 h, RT, 18%; (4) DIPEA, N2, dry DMF, 1 h, RT, 
18%. 
 
 Pharmacology.  Initially, the OR binding affinities of the six congeners were measured via a 
competitive radioligand binding assay using [3H]diprenorphine in membrane preparations of CHO-
FlpIn cells stably expressing the human MOR. The results (Table 1) revealed some clear trends.  
Firstly, the amide linker is generally better tolerated than the imide linker; three of the four compounds 
(8, 10 and 11) with amide linkers have a higher binding affinity than the imide congeners.  The amide 
equivalent (8) of the protected, unreduced imide congener (13) displayed approximately 35-fold higher 
affinity for the ORs.  One possible explanation for this is that the amide group is more flexible than the 
imide group and is thus able to rotate itself into a position where it can make more favorable hydrogen-
bonding interactions with surrounding residues, or minimize unfavorable steric interactions. The 
reduction of the olefin is associated with a 2–3-fold increase in OR affinity (10 vs. 8 and 11 vs. 9), 
which may again be due to increased flexibility.  Finally, the Boc-protected congeners, 8, 10 and 13, 
exhibited approximately 26-, 49- and 8-fold higher OR affinity compared to the respective deprotected 
analogs, 9, 11 and 14.  This indicates not only that the linker is well tolerated, but that it is sufficiently 
long that reasonably bulky groups can be attached to its terminus without disrupting binding. 
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Table 1. OR affinities (pKi) of congeners, measured using a radioligand binding assay in membrane 
preparations of CHO FlpIn cells stably expressing human MOR. 
 
Compound R Single/Double Bond pKi 
DAMGO -- -- 5.66 ± 0.08 
Buprenorphine -- --         8.8† 
8 -(CH2)6NHBoc Double 8.13 ± 0.08
§ 
9 -(CH2)6NH2.2HCl Double 6.71 ± 0.08 
10 -(CH2)6NHBoc Single 8.66 ± 0.08 
11 -(CH2)6NH2.2HCl Single 6.97 ± 0.08 
13 -(CH2)6NHBoc Double 6.58 ± 0.07 
14 -(CH2)6NH2.2HCl Double 5.69 ± 0.07 
† from IUPHAR database.58 
§ Errors represent ± SEM of 3 independent experiments 
 
 
 The efficacy of congeners 8–14 to stimulate ERK phosphorylation via the MOR was also tested 
in CHO FlpIn cells stably expressing human MOR.  Time-course experiments involving incubation of 
the congeners (10 µM) with MOR-overexpressing cells for a 30-min period showed no ERK 
phosphorylation in the presence of any of the congeners (data not shown), indicating that all congeners 
have no detectable agonist activity at this signaling pathway at this time point. 
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 Incubation of increasing concentrations of each of the fluorescent probes with an EC50 
concentration of a MOR, DOR or KOR agonist ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO), 
SNC80 and ICI199441, respectively) in CHO FlpIn cells stably expressing human MOR, DOR or 
KOR, resulted in an inhibition of agonist-induced ERK phosphorylation in all cases (Figure S21) (in 
the case of the DOR and KOR, time course experiments akin to those performed with the congeners 
and MOR-overexpressing cells were also conducted, indicating that all congeners have no detectable 
agonist activity at this signaling pathway after 30 min (data not shown)). Assuming competitive 
binding, the affinities (pA2) of the fluorescent probes for the three receptor subtypes (Table 2) were 
determined using the Gaddum-Schild equation as per Lane et al.59 Each of the probes showed high 
affinity for the MOR, together with a strong preference for this OR subtype over KOR and DOR 
(selectivity ratios of 9–45 and > 200, respectively). The selectivity ratios for 2 and 4 indicate that they 
are amongst the most MOR-selective fluorescent opiate antagonists reported to date.25–27 
 
Table 2. pA2 values of the fluorescent probes at the three ORs (n = 3).  Agonists used were DAMGO 
(MOR), SNC80 (DOR) and ICI199441 (KOR).   
Compound pA2 (MOR) pA2 (DOR) pA2 (KOR) MOR/KOR 
selectivity 
Agonist (pEC50) 7.67 ± 0.01§ 8.18 ± 0.07 10.32 ± 0.04  - 
1 7.87 ± 0.08 < 5 # 6.91 ± 0.18 9 
2 8.37 ± 0.07 < 5 6.72 ± 0.25 45 
3 7.31 ± 0.22 < 5 6.30 ± 0.04 10 
4 8.01 ± 0.27 < 5 6.37 ± 0.04 44 
§ Errors represent ± SEM of three independent experiments performed in triplicate. # < 5 indicates that 
no fitting could be performed within the concentrations tested, indicating very low affinity. 
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  Imaging studies.  The absorption and emission profiles of the synthesized probes (Figure S23) 
were recorded using a FlexStation 3 plate reader in both hydrophilic (HEPES buffered saline solution, 
HBSS) and hydrophobic (dimethylsulfoxide, DMSO) environments at a concentration of 10 μM.  
These solvents were used to represent the polar aqueous and comparatively non-polar ligand binding 
site environment within an OR, respectively.  Such measurements were necessary to ensure that 
appropriate excitation wavelength and dichroic emission filters were used in the subsequent imaging 
experiments. 
 In general, all of the observed excitation and emission maxima (Table S1) closely matched those 
reported in the literature for the corresponding “free” fluorophore.50,60,61 All probes experienced a 
significant decrease in emission intensity and, in most cases, a hypsochromic shift in maxima upon 
moving from DMSO to HBSS, which is particularly useful from the perspective of developing 
fluorescent displacement-style binding assays. Unfortunately, no signal could be detected for the 
tetrazine probe, 4, even at 100 μM, despite the fact that yellow fluorescence could be observed under 
long-wavelength UV irradiation (TLC lamp).  
 It was encouraging that the BODIPYTM 630/650 derivative (2) exhibited the highest MOR 
affinity (vide supra) as it has particularly favorable photophysical properties for imaging and assay 
applications.  Most BODIPY fluorophores have high quantum yields, often approaching unity, and a 
high molar extinction coefficient (101,000 cm-1M-1).62  Probe 2 displayed bright fluorescence in a 
relatively non-polar environment (DMSO), but almost full quenching of fluorescence in an aqueous 
environment (Figure S23), which would obviate the need for a washing step in a fluorescent 
displacement-style binding assay. 
 Single-time point confocal images of human embryonic kidney cells (HEK) stably expressing the 
human MOR-GFP fusion protein were captured after incubation with each of the probes (Figure 3).  
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The MOR was expressed with green fluorescent protein at its C-terminus so that the binding specificity 
of each probe could be assessed from the degree of co-localization of probe and GFP fluorescence.  
 The strong binding affinity and favorable photophysical properties of BODIPYTM 630/650 
allowed probe 2 to be clearly imaged at relatively low concentration (5 nM).  There was a high degree 
of colocalization of the probe with MOR-GFP and significant displacement of binding by the non-
fluorescent antagonist, naloxone, providing strong evidence that binding is specifically to the MOR. 
However, the fact that not all the fluorescent signal was lost upon incubation with a large excess of the 
unlabeled MOR-specific ligand indicates some degree of non-specific interaction of 2 with the cellular 
membrane (Figure 3). 
 The concentration required to image binding of probe 3 (50 nM) was higher than that required for 
2, consistent with its almost 10-fold lower affinity for the MOR.  Unlike 2, this probe could be almost 
completely displaced using excess naloxone (Figure 3), again indicating that it binds specifically to the 
MOR, but also that the use of a more hydrophilic sulfo-Cy5 fluorophore reduces non-specific 
interaction with the cellular membrane.   
 Displacement of 3 with naloxone was also accompanied by a large decrease in fluorescence 
intensity, consistent with the reduced fluorescence of this probe in an aqueous environment.  It should 
be noted that no wash steps were performed in these imaging experiments, so the observed reductions 
in fluorescence were not simply due to a concentration gradient-driven re-equilibration process.  
 In the case of 1 and 4, no fluorescence was observed after incubating cells with the probes; hence 
their quantum yields appear to be inadequate for imaging purposes under the conditions employed here. 
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Figure 3. Live cell confocal imaging of 2 and 3 in cells expressing MOR-GFP. Confocal images of 
HEK-MOR-GFP cells incubated with probes 2 or 3 (30 min, 37oC) at the concentrations shown, with 
and without prior incubation with naloxone (1 µM, 30 min, 37oC).  All images are of a 102 µm × 102 
µm area and are representative images of those obtained in three separate experiments. 
 
 Fluorescent binding assays.  The imaging studies suggested that probes 2 and 3 may be suitable 
for use in a fluorescence-based competition binding assay as per Stoddart et al.63  As a prelude to this, 
experiments were performed to establish an appropriate pre-incubation time (Figure 4). 
2 (5 nM) 
2 (5 nM) 
+ 1 M Naloxone 
3 (50 nM) 
3 (50 nM) 
+ 1 M Naloxone 
MOR-GFP Ligand Merge 
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 The results for the sulfo-Cy5-bearing probe 3 (Figure 4, top panels) showed that equilibrium was 
rapidly reached (within 5 min), whilst for the BODIPY-bearing probe 2 (Figure 4, bottom panels), the 
system was still equilibrating after 30 minutes.  Experiments performed in the presence of an excess of 
naloxone again confirmed that there was minimal non-specific interaction in the case of 3, and a single 
wash step removed essentially all of the bound probe, reflective of fast dissociation kinetics. In 
contrast, significant amounts of 2 bound to the cells in the presence of naloxone, and washing produced 
very little change in fluorescence, indicating a high degree of non-specific interaction and/or slower 
dissociation kinetics. Given these results, 3 was considered the most appropriate probe for use in a 
fluorescent binding assay. 
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Figure 4. Determining the suitability of 2 and 3 for a live cell fluorescence-based competition 
binding assay.  Confocal  images obtained on the IX Ultra of HEK-MOR cells incubated with 2 (10 
nM) and 3 (100 nM) for 5–30min at 37oC. Cells in the bottom three rows of the plate were coincubated 
with naloxone (1 µM) for their respective time periods, and those in the five right-hand side columns 
100 nM 3 
100 nM 3 
+ 1 M 
Naloxone 
5 min 15 min 30 min 
Washed 
20 min 10 min 5 min 15 min 30 min 
Not washed 
20 min 10 min 
10 nM 2 
10 nM 2 
+ 1 M 
Naloxone 
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were washed once after incubation.  The image is a montage of four images taken per well and is 
representative of images taken in three separate experiments.   
 To confirm that 3 was suitable for use in determining the affinity of unlabeled ligands, MOR 
receptor-expressing cells were co-incubated with 3 (50 nM) and increasing concentrations of either the 
MOR agonists, DAMGO and dermorphin, or the MOR antagonists, diprenorphine, naloxone, 
naltrexone and naloxonazine, with xanthine amine congener (XAC), an adenosine receptor antagonist 
included as a negative control.  The affinity of each test compound (pKi, Table 3) was determined from 
the IC50 value obtained from the competition curve constructed by measuring the decrease in 
fluorescence intensity caused by the compound competing with 3 for the MOR (Figure 5). 
 
Figure 5. Competition binding curves. Competition curves for displacement of 3 (50 nM) by MOR-
binding test compounds and XAC, constructed by measuring the decrease in fluorescence intensity 
with increasing concentrations of test compound.  Each data point represents mean ± SEM of three 
experiments each performed in duplicate.   
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 For the antagonists, excellent agreement was found between the pKi values obtained from the 
automated confocal imaging and literature values derived from radioligand binding assays (Table 3).  
In contrast, the pKi values obtained for the agonists were significantly lower than the literature 
values.64–67  However, it is of note that the literature values were obtained from radioligand binding 
assays using a titrated agonist ([3H]DAMGO). As such, the affinities reported in literature represent the 
high-affinity G protein-coupled state of the receptor.  As our fluorescent ligand competition binding 
assays were performed in whole cells, where the intracellular concentration of GDP is significantly 
higher than GTP, the receptor will exist predominantly in the low-affinity G protein uncoupled state 
state, which is reflected in the lower agonist affinities obtained. As expected, no decrease in 
fluorescence intensity was observed in the presence of XAC, meaning that there is no decrease in 
binding of the probe over time and its binding is specific to the MOR. 
 
Table 3. MOR affinity (pKi) of test compounds, as determined by Cheng-Prusoff analysis of data 
presented in Figure 5 (n = 3).  Literature values derived from radioligand binding assays are included 
for comparison.64–67 
Compound pKi from fluorescent binding assay  Literature pKi 
DAMGO 7.06 ± 0.13§ 8.9 
Dermorphin 7.71 ± 0.08 8.8 
Diprenorphine 9.91 ± 0.08 9.7 
Naloxonazine 8.84 ± 0.05 8.5 
Naloxone 8.94 ± 0.11 8.9 
Naltrexone 9.56 ± 0.04 9.7 
§ Errors represent ± SEM of three independent experiments performed in duplicate. 
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 CONCLUSION  
 In conclusion, we have successfully synthesized four new non-peptidic fluorescent OR ligands 
based on the buprenorphine scaffold. All four compounds acted as antagonists at the MOR, DOR and 
KOR, exhibiting highest affinity for the MOR. Although we have not yet explored the NOR-binding 
properties of the compounds, the fact that buprenorphine has affinity for this fourth OR subtype 
suggests that this would be a worthwhile subject for future studies. The ligand linked to the sulfo-Cy5 
fluorophore (3) was found to display the best properties for use in imaging and fluorescent binding 
assays, exhibiting rapid and reversible MOR binding, characterized by increased fluorescence in the 
bound state. It was successfully used to image the MOR in HEK cells overexpressing this receptor, as 
well as to measure the MOR affinities of a series of ligands via a fluorescent competitive binding assay. 
We envisage that this compound will prove useful as a research tool for further investigating the 
pharmacology of the MOR in in vitro studies, as well as in developing new OR agonists/antagonists 
with improved efficacy and side-effect profiles. 
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 EXPERIMENTAL SECTION  
Chemistry. All chemicals were purchased from Sigma-Aldrich Pty, Invitrogen, Matrix Scientific, 
Tocris Bioscience or Merck Group Ltd and used without purification, unless otherwise indicated.  tert-
Butyl-(6-aminohexyl)carbamate, triaminoguanidine hydrochloride, 3,6-bis(3,5-dimethyl1H-pyrazol-1-
yl)-1,2-dihydro-s-tetrazine, 3,6-bis(3,5-dimethyl1H-pyrazol-1-yl)-s-tetrazine, 3,6-dihydrazinyl-s-
tetrazine, 15 and 16 were synthesized as per previous literature.51,54,68  All solvents were reagent grade 
(chloroform, dichloromethane, ethyl acetate, methanol, acetonitrile).  Microwave reactions were 
conducted in a Biotage Initiator™, in 0.5–2.0 mL vials unless otherwise indicated, according to the 
manufacturer’s instructions.  Where indicated, reduction reactions were performed using a Thalesnano 
Hydrogenation Reactor (H-CubeTM) continuous flow apparatus system using a 10% PD/C CatcartTM 
cartridge with parameters as indicated.  Thin layer chromatography (TLC) was performed on Merck 
Silica Gel 60 F254 plates.  TLC plates were visualized using a UV lamp at 254 nm or through the use 
of KMnO4 staining agent.  
1H, 13C and 19F nuclear magnetic resonance (NMR) spectra were recorded at 
400.13 MHz, 100.61  and 376 MHz, respectively, using an Avance III Nanobay 400 MHz Bruker 
spectrometer coupled to the BACS 60 automatic sample changer.  Data acquisition and processing was 
managed using Topspin software package version 3.  Chemical shifts (δ) were measured in parts per 
million (ppm) referenced to an internal standard of residual solvent; 3.31 ppm and 49.00 ppm for 
deuterated methanol, 7.26 ppm and 77.16 ppm for deuterated chloroform, 2.50 ppm and 39.52 ppm for 
deuterated dimethylsulfoxide (d6-DMSO), for proton and carbon spectra, respectively.  Spectroscopic 
data are given using the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; br, broad; J, coupling constant; app, apparent pentet.  Analytical high-performance liquid 
chromatography (HPLC) was carried out on a Waters 2690 Separation Module coupled with a Waters 
996 Photodiode Array Detector with a Phenomenex Luna 5 micron C8 150 × 4.6 mm column using the 
following elution protocol: 0–10 min, gradient from 0% to 80% buffer B/20% buffer A, 10–11 min, 
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80% buffer B/20% buffer A, 11–12 min, gradient from 80% buffer B/20% buffer A to 100% buffer B; 
12–22 min, 100% B (buffer A = 99.9% H2O, 0.1% TFA; buffer B = 80% ACN, 19.9% H2O, 0.1% 
TFA).  Compound 3 was analyzed using an Agilent 1260 Infinity Analytical HPLC using a Zorbax 
Eclipse Plus Rapid Resolution 3.5 micron C18 4.6 x 100 mm, column with a 1260 infinity diode array 
detector, and the following elution protocol: 0–9 min, gradient from 5% buffer D/ 95% buffer C to 
100% buffer D; 9–10 min, 100% buffer D (buffer C = 99.9% H2O, 0.1% TFA; buffer D = 99.9% ACN, 
0.1% TFA).  The purities of all compounds submitted for biological testing were hence determined to 
be ≥ 95%.  Preparatory HPLC purification was carried out on an Agilent 1260 Prep HPLC with an 
Alltima 5 micron C8 250 x 22 mm column and a 1260 Infinity diode array detector VL, and the 
following elution protocol: 0–9 min, gradient from 5% buffer D/ 95% buffer C to 100% buffer D; 9–10 
min, 100% D (buffer C = 99.9% H2O, 0.1% TFA; buffer D 99.9% ACN, 0.1% TFA). High-resolution 
mass spectrometric (HRMS) analyses were performed on a Waters LCT TOF LC/MS Mass 
Spectrometer coupled to a 2795 Alliance Separations module. All data were acquired and mass 
corrected via a dual-spray Leucine Enkephaline reference sample. Mass spectra were created by 
averaging the scans across each peak and background subtracted of the TIC. Acquisition and analysis 
were performed using the MassLynx software version 4.1.  The mass spectrometer conditions were as 
follows: electrospray ionization mode, desolvation gas flow of 550 L h-1, desolvation temperature of 
250 °C, source temperature of 110 °C, capillary voltage of 2400 V, sample cone voltage of 60 V, scan 
range acquired between 100–1500 m/z, one sec scan times and internal reference ions for positive ion 
mode (Leucine Enkephaline) of 556.2771. Reverse-phase chromatography was performed using 
Davasil C18-modified reverse-phase silica using buffers C and D. Liquid chromatography-mass 
spectrometry (LC-MS) was performed using an Agilent 6100 Series Single Quad LC/MS coupled to an 
Agilent 1200 Series HPLC with the following conditions and equipment for MS: 1200 Series G1311A 
Quaternary pump, 1200 Series G1329A Thermostatted Autosampler, 1200 Series G1314B Variable 
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Wavelength Detector.  MS conditions: Quadrupole ion source, multimode-ES ion mode, 300 °C drying 
gas temperature, 200 °C vaporizing temperature, capillary voltage of 2000 V (positive), capillary 
voltage of 4000 V (negative), scan range between 100–1000 m/z with an 0.1 sec step size and a 10 min 
acquisition time.  LC equipment and conditions were as follows: reverse-phase HPLC analysis on a 
Luna 5 micron C8(2) 50 x 4.6 mm column using a column temperature of 30 °C, an injection volume 
of 5 µL, and the following elution protocol: 0–4 min, gradient from 5% buffer F/95 % buffer E to 
100% buffer F; 4–7 min, 100% buffer F; 4–7 min, gradient from 100% buffer F to 5% F/95 % buffer E 
(buffer E = 99.9% H2O, 0.1% formic acid; buffer F: 99.9% ACN, 0.1% formic acid). Detection was at 
254 nm. Emission and excitation spectra were obtained using a FlexStation 3.  All measurements were 
made on 10 µM solutions of compounds in HBSS or DMSO, with the solvent signals subtracted from 
the relevant spectra. The following parameters were used.  Compound 1: Emission spectra: excitation 
at 400 nm, cutoff at 420 nm, scan emission from 430–750 nm at 2 nm steps.  Excitation spectra: 
emission at 580 nm, cutoff at 570 nm, scan excitation from 300–550 nm at 2 nm steps.  Compound 2: 
Emission spectra: excitation at 360 nm, cutoff at 420 nm, scan emission from 430–710 nm at 2 nm 
steps.  Excitation spectra: emission at 700 nm, cutoff at 695 nm, scan excitation from 300–680 nm at 2 
nm steps.  Compound 3: Emission spectra: excitation at 590 nm, cutoff at 610 nm, scan emission from 
620–800 nm at 2 nm steps.  Excitation spectra: emission at 700 nm, cutoff at 695 nm, scan excitation 
from 300–680 nm at 2 nm steps.  All measurements were normalized and plotted using GraphPad 
Prism 6 (GraphPad Software, San Diego, CA). 
 
 (3R,6S,7R,7aR,12bS)-6-((6-(3-(6-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-
yl)propanamido)hexyl)carbamoyl)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-
ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium 2,2,2-trifluoroacetate (1). Compound 11a 
(351 mg, 0.649 mmol) and DIPEA (340 µl, 1.95 mmol) were dissolved in dry DMF (2 mL).  3-(4-
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Amino-1,8-naphthalimido)propanoic acid (140 mg, 0.492 mmol) and  HCTU (247 mg, 0.597 mmol) 
were added to this solution, pre-dissolved in dry DMF (2 mL).  The reaction mixture was left to stir 
under a nitrogen atmosphere for 2 h.  Compound 1 was obtained as a green-yellow solid after reverse-
phase column chromatography (0–40% buffer D in C) and lyophilization (201 mg, 48%).  1H NMR 
(MeOD) δHH 8.49–8.45 (m, 2H), 8.25 (d, J = 8.4 Hz, 1H), 7.62 (dd, J = 8.4, 7.4 Hz, 1H), 6.86 (d, J = 
8.4 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 8.1 Hz, 1H), 4.56 (d, J = 1.9 Hz, 1H), 4.40 (t, J = 7.0 
Hz, 2H), 3.70 (d, J = 6.9 Hz, 1H), 3.41 (s, 3H), 3.29–3.28 (m, 1H), 3.17 – 3.06 (m, 5H), 2.99 (s, 3H), 
2.90 (dd, J = 19.9, 7.1 Hz, 1H), 2.73–2.69 (m, 1H), 2.60–2.52 (m, 3H), 2.30 (td, J = 13.7, 5.2 Hz, 1H), 
2.07–1.87 (m, 3H), 1.55–1.41 (m, 7H), 1,25–1.23 (m, 4H), 0.84–0.78 (m, 1H); 13C NMR (MeOD) δCH 
174.0, 173.5, 166.0, 165.4, 154.4, 147.5, 140.8, 135.5, 132.5, 131.3, 131.1, 130.2, 125.2, 124.3, 123.1, 
121.2, 121.0, 119.4, 107.7, 109.4, 92.6, 77.1, 64.8, 52.2, 47.7, 45.4, 44.4, 42.7, 40.3, 40.2, 37.8, 37.1, 
35.8, 33.1, 30.7, 30.1, 30.0, 29.7, 27.3, 27.2, 25.2, 19.0; 19F NMR (MeOD) δ -76.8.  HRMS (ESI-TOF) 
m/z C42H49N5O7 [MH]
+ calcd, 735.3632; found, 735.3622.  
 5,5-Difluoro-3-((Z)-4-(2-((6-((6-((3R,6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-
1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-6-
carboxamido)hexyl)amino)-6-oxohexyl)amino)-2-oxoethoxy)styryl)-7-(thiophen-2-yl)-5H-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide 2,2,2-trifluoroacetate (2).  Compound 11b 
(13.8 mg, 19.8 µmol), DIPEA (10 µl, 57.4 µmol) and 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-
diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoic acid, succinimidyl ester (6.70 mg, 10.1 µmol) 
was dissolved in dry DMF (500 µl).  The reaction was left to stir under a nitrogen atmosphere for 4 h 
with the exclusion of light.  The resulting solution was added to MeOH and purified by reverse-phase 
prep HPLC (60–100% buffer D in C) to give compound 2 as a blue solid after lyophilization (3.60 mg, 
32%).  1H NMR (MeOD) δHH 8.12 (dd, J = 3.8, 1.0 Hz, 1H), 7.65–7.60 (m, 3H), 7.55 (d, J = 4.0 Hz, 
2H), 7.37 (s, 1H), 7.22–7.20 (m, 2H), 7.14 (d, J = 4.4 Hz, 2H), 7.06 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 4.3 
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Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 4.57 (s, 2H), 4.51 (d, J = 1.9 Hz, 1H), 3.62 
(d, J = 6.9 Hz, 1H), 3.38 (s, 3H), 3.29–3.20 (m, 3H), 3.16–3.02 (m, 4H), 2.98–2.78 (m, 4H), 2.71–2.66 
(m, 1H), 2.53–2.40 (m, 1H), 2.23 (td, J = 14.0, 5.2 Hz, 1H), 2.15 (t, J = 7.4 Hz, 2H), 2.07–1.96 (m, 
1H), 1.96–1.77 (m, 2H), 1.68–1.21 (m, 18H), 0.82–0.74 (m, 1H);  19F NMR (MeOD) δ -77.0.  HRMS 
(ESI-TOF) m/z C56H65BF2N6O7S [MH]
+ calcd, 1013.4733; found, 1013.4731. 
 2-((1E,3E,5E)-5-(1-Ethyl-3,3-dimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-1-(6-((6-
((6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-
methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)amino)-6-oxohexyl)-3,3-dimethyl-3H-
indol-1-ium-5-sulfonate, 2,2,2-trifluoroacetate salt (3).  Compound 11b (19.3 mg, 27.7 µmol) was 
dissolved in dry DMF (200 µl).  DIPEA (40 µl, 230 µmol), Cy5 (15 mg, 22.8 µmol) and PyBOP (14.7 
mg, 28.3 µmol) were added to this solution, pre-dissolved in dry DMF (200 µL).  The reaction mixture 
was left to stir under a nitrogen atmosphere for 1 h with the exclusion of light.  The resulting solution 
was added to MeOH (1 mL) and purified by reverse-phase prep HPLC (4–37% buffer D in C) to give 
compound 3 as a blue solid after lypholization (5.00 mg, 18%).  1H NMR (MeOD) δHH 8.53–8.16 (m, 
2H), 8.02–7.76 (m, 4H), 7.34 (dd, J = 15.1, 8.5 Hz, 2H), 6.85–6.58 (m, 3H), 6.44–6.30 (m, 2H), 4.58 
(s, 1H), 4.22–4.14 (m, 4H), 3.68 (d, J = 6.9 Hz, 1H), 3.40 (s, 3H), 3.22–3.14 (m, 6H), 3.00 (s, 3H), 
2.97–2.71 (m, 2H), 2.67–2.50 (m, 1H), 2.47–2.28 (m, 1H), 2.18 (t, J = 6.8 Hz, 2H), 1.99–1.64 (m, 
20H), 1.51–1.26 (m, 16H), 0.83–0.74 (m, 1H);  19F NMR (MeOD) δ -77.3.  HRMS (ESI-TOF) m/z 
C60H77N5O11S2 [MH]
+ calcd, 1108.5134; found, 1108.5113. 
 (3R,6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-6-((6-(4-((6-methoxy-1,2,4,5-tetrazin-3-
yl)oxy)butanamido)hexyl)carbamoyl)-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-
methanobenzofuro[3,2-e]isoquinolin-3-ium 2,2,2-trifluoroacetate (4).  Compound 11b (132 mg, 189 
µmol) was dissolved in dry DMF (1 mL).  DIPEA (150 µl, 861 µmol) and 19 (91.3 mg, 293 µmol) 
were added and the reaction mixture left to stir under a nitrogen atmosphere for 1 h. 1:3 (v/v) 
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IPA:CHCl3 (50 mL) was then added and the mixture washed with H2O (3 × 50 mL) and brine (30 mL).  
The organic layer was dried with MgSO4 and the solvent removed in vacuo.  The resulting oil was 
purified by reverse-phase prep HPLC (5–100% buffer D in C).  The aqueous phase was washed with 3 
× 100 mL 1:3 (v/v) IPA/CHCl3 and lyophilized to give compound 4 as a pink solid (11.2 mg, 18%).  
1H 
NMR (MeOD) δHH 6.74 (d, J = 8.1 Hz, 1H), 6.66 (d, J = 8.1 Hz, 1H), 4.60–4.56 (m, 3H), 4.21 (s, 3H), 
3.70 (d, J = 7.1 Hz, 1H), 3.42 (s, 3H), 3.20–3.08 (m, 5H), 2.99–2.89 (m, 4H), 2.72 (dd, J = 10.0, 5.6 
Hz, 1H), 2.53–2.40 (m, 3H), 2.32–2.15 (m, 3H), 2.10–1.97 (m, 2H), 1.91–1.83 (m, 1H), 1.57–1.42 (m, 
6H), 1.42–1.28 (m, 6H), 0.89–0.80 (m, 1H); 19F NMR (MeOD) δ -77.2.  HRMS (ESI-TOF) m/z 
C34H47N7O7 [MH]
+ calcd, 665.3537; found, 665.3559. 
 (4R,7aR,12bS)-9-((tert-Butyldimethylsilyl)oxy)-7-methoxy-3-methyl-2,3,4,7a-tetrahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinoline (6). Compound 5 (400 mg, 1.35 mmol), imidazole (362.6 mg, 
5.33 mmol) and tert-butyldimethylsilyl chloride (533 mg, 3.54 mmol) were dissolved in dry DMF (1 
mL).  The dark brown solution was allowed to stir for approximately 1 min under a nitrogen 
atmosphere, after which the mixture solidified, indicating reaction completion.  The solid was dissolved 
in H2O (100 mL) and Et2O (100 mL) and washed with more Et2O (3 × 100 mL).  The organic layers 
were then washed with brine (100 mL), dried with Na2SO4 and the solvent removed in vacuo.  The 
brown residue was purified by column chromatography (1% TEA in CHCl3) to give compound 6 as a 
slightly brown oil which solidifies on standing (83%, 458.5 mg).  All characterization data were in 
agreement with Klein et al.69 
 (4R,7R,7aR,12bS,14S)-Methyl-9-((tert-butyldimethylsilyl)oxy)-7-methoxy-3-methyl-1,2,3,4,7,7a-
hexahydro-7,4a-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-14-carboxylate (7). Compound 6 
(5.00 g, 12.2 mmol) was dissolved in methyl acrylate (10 mL, 111 mmol) and heated by microwave 
irradiation to 130 oC for 3 h.  The remaining methyl acrylate was removed in vacuo and the resulting 
oil purified by column chromatography and recrystallized from minimal hot methanol to give 
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compound 7 as faint yellow crystals (69%, 4.22 g).  1H NMR (MeOD) δHH 6.50 (d, J = 8.1 Hz, 1H), 
6.46 (d, J = 8.1 Hz, 1H), 5.58 (d, J = 8.9 Hz, 1H), 5.51 (d, J = 8.8 Hz, 1H), 4.68 (d, J = 1.2 Hz, 1H), 
3.63 (s, 3H), 3.55 (s, 3H), 3.22 (dd, J = 12.5, 6.1 Hz, 2H), 3.09–2.88 (m, 2H), 2.58–2.39 (m, 3H), 2.36 
(s, 3H), 2.04 (td, J = 12.8, 5.6 Hz, 1H), 1.77 (dd, J = 13.3, 2.3 Hz, 1H), 1.42 (dd, J = 11.5, 5.1 Hz, 1H), 
0.97 (s, 9H), 0.15 (s, 3H), 0.13 (s, 3H); 13C NMR (MeOD) δCH 175.5, 151.1, 138.0, 136.6, 135.6, 
130.3, 128.0, 122.4, 120.7, 93.0, 82.3, 61.4, 52.3, 52.3, 49.9, 46.7, 44.2, 43.8, 43.5, 34.4, 31.6, 26.2, 
23.4, 19.2, -4.3. LC-MS ESI+ m/z [M + H] = 498.3. 
 tert-Butyl-(6-((4R,7R,7aR,12bS,14S)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,7,7a-hexahydro-
7,4a-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-14-carboxamido)hexyl)carbamate (8). 
Compound 7 (2.72 g, 5.47 mmol) was dissolved in THF (30 mL) and 1 M LiOH (30 mL) and left to 
stir for 14 h.  The solution was neutralized with 5 M HCl (6 mL), producing a precipitate.  The solvent 
was removed in vacuo.  HOBt (1.58 g, 11.7 mmol), compound 8 (2.62 g, 12.1 mmol) and the solid 
residue were then dissolved in dry DMF (25 mL).  DIPEA (4.8 mL, 27.6 mmol) and EDC.HCl (2.37 g, 
12.4 mmol) were dissolved in dry DMF (25 mL) and added via syringe.  The reaction was allowed to 
stir at room temperature under nitrogen gas for 14 h.  The solvent was removed in vacuo, and the 
residue taken up in H2O (250 mL) and Et2O (250 mL).  These layers were separated and the aqueous 
layer was washed with more Et2O (3 × 150 mL).  All organic layers were combined and dried with 
Na2SO4 and the solvent removed in vacuo.  The resulting oil was purified by column chromatography 
(0–2% MeOH in CHCl3) and the relevant fractions concentrated to dryness in vacuo to give compound 
8 as a pale yellow solid (44%, 1.37 g).  1H NMR (CDCl3) δHH 6.60 (d, J = 8.1 Hz, 1H), 6.47 (d, J = 8.1 
Hz, 1H), 6.13–6.08 (m, 1H), 5.83 (d, J = 8.8 Hz, 1H), 5.54 (d, J = 8.8 Hz, 1H), 4.57 (bs, 1H), 4.54 (d, J 
= 1.0 Hz, 1H), 3.57 (s, 3H), 3.31–3.14 (m, 4H), 3.12–3.00 (m, 3H), 2.61 (dd, J = 9.4, 6.3 Hz, 1H), 2.52 
(dd, J = 11.8, 5.0 Hz, 1H), 2.44–2.28 (m, 5H), 2.04–1.88 (m, 1H), 1.81 (dd, J = 13.0, 2.4 Hz, 1H), 
1.52–1.38 (m, 15H), 1.33–1.26 (m, 4H); 13C NMR (CDCl3) δCH 172.6, 156.2, 146.7, 138.0, 137.0, 
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134.01, 127.5, 125.8, 120.0, 116.7, 94.3, 80.7, 79.2, 60.1, 52.8, 47.5, 45.6, 44.6, 43.6, 43.2, 40.4, 39.4, 
33.3, 31.2, 30.1, 29.5, 28.5, 26.4, 26.3, 22.6.  HRMS (ESI-TOF) m/z C32H45N3O6 [MH]
+ calcd, 
568.3381; found, 568.3370.   
 (3R,4R,7R,7aR,12bS,14S)-14-((6-ammoniohexyl)carbamoyl)-9-hydroxy-7-methoxy-3-methyl-
1,2,3,4,7,7a-hexahydro-7,4a-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium chloride (9). 
Compound 8 (317 mg, 0.558 mmol) was dissolved in 4 M HCl in dioxane (5 mL) and allowed to stir 
for 1 h.  The reaction mixture was then neutralized with sat. NaHCO3, the solvent rmeoved in vacuo 
and the remaining residue purified by column chromatography (89:10:1 CHCl3:MeOH:NH4OH).  After 
concentrating the relevant fractions in vacuo, the resulting oil was dissolved in 1 M HCl (20 mL) and 
lyophilized to give compound 9 (bis-HCl salt) as a pale orange solid (39%, 118 mg).  1H NMR 
(MeOD) δHH 6.61 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.2 Hz, 1H), 5.87 (d, J = 8.6 Hz, 1H), 5.56 (d, J = 
8.8 Hz, 1H), 4.75 (s, 1H), 4.17 (d, J = 4.5 Hz, 1H), 3.60 (s, 3H), 3.46 (t, J = 18.4 Hz, 1H), 3.37 (t, J = 
8.3 Hz, 1H), 3.27–3.17 (m, 2H), 3.15–3.10 (m, 2H), 3.05 (s, 3H), 3.01–2.98 (m, 1H), 2.93 (t, J = 7.2 
Hz, 3H), 2.34 (t, J = 11.8 Hz, 1H), 2.12 (d, J = 12.9 Hz, 1H), 1.74–1.60 (m, 3H), 1.57–1.49 (m, 2H), 
1.45–1.35 (m, 4H); 13C NMR (MeOD) δCH 173.8, 148.6, 140.7, 133.5, 133.0, 128.7, 124.3, 121.4, 
118.9, 93.7, 81.6, 63.7, 53.5, 48.3, 47.4, 44.9, 43.9, 42.9, 40.6, 40.1, 31.5, 31.3, 30.1, 28.4, 27.0, 26.9, 
25.7.  HRMS (ESI-TOF) m/z C27H37N3O4 [MH]
+ calcd, 468.2857; found, 468.2873. 
 tert-Butyl-(6-((4R,6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-
4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)carbamate (10).  
Compound 8 (200.7 mg, 0.354 mmol) was dissolved in ethanol (10 mL) and passed through a H-cube 
apparatus under the following conditions: 10 bar pressure, 25oC, 1 mL min-1 flow rate.  After 2 h, the 
reaction was complete as indicated by LCMS.  The solvent was removed in vacuo to give compound 10 
as a white solid (86%, 174 mg).  1H NMR (MeOD) δHH 6.74 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 8.1 Hz, 
1H), 4.58 (dd, J = 6.6, 2.0 Hz, 1H), 3.69 (d, J = 6.9 Hz, 1H), 3.49–3.33 (m, 4H), 3.30–3.23 (m, 2H), 
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3.18–3.06 (m, 2H), 3.06–2.98 (m, 2H), 2.98–2.83 (m, 4H), 2.80–2.68 (m, 1H), 2.59–2.47 (m, 1H), 2.31 
(td, J = 14.1, 5.4 Hz, 1H), 2.01 (ddd, J = 17.9, 13.9, 4.6 Hz, 2H), 1.95–1.86 (m, 1H), 1.73–1.21 (m, 
19H), 0.82 (dd, J = 17.5, 7.7 Hz, 1H); 13C NMR (MeOD) δCH 174.0, 158.6, 147.5, 140.8, 131.1, 124.3, 
121.2, 119.4, 92.7, 79.8, 77.0, 64.8, 52.2, 47.7, 45.4, 44.4, 42.6, 41.2, 40.5, 37.1, 33.1, 30.9, 30.5, 30.4, 
29.7, 28.8, 27.5, 25.2, 19.0.  HRMS (ESI-TOF) m/z C32H47N3O6 [MH]
+ calcd, 570.3538; found, 
570.3538.  
  (4R,4aS,6S,7R,7aR,12bS)-6-((6-Ammoniohexyl)carbamoyl)-9-hydroxy-7-methoxy-3-methyl-
1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium chloride 
(11a). Compound 8 (641 mg, 1.13 mmol) was dissolved in ethanol (30 mL) and run through the H-
cube apparatus under the following conditions: 10 bar pressure, 25oC, 1 mL min-1 flow rate.  After 10 
h, the reaction was complete as indicated by LCMS.  The solvent was removed in vacuo and purified 
by column chromatography (6–8% MeOH in CHCl3).  The relevant fractions were evaporated to 
dryness. 4 M HCl (30 mL) was added and this solution was allowed to stir for 30 min.  The solution 
was lyophilized to give compound 11 as a green solid in the bis-HCl salt form (29%, 174 mg).  1H 
NMR (1:1 MeOD:D2O) δHH 6.77 (d, J = 7.9 Hz, 1H), 6.70 (d, J = 7.9 Hz, 1H), 4.71 (s, 1H), 3.69 (d, J = 
5.6 Hz, 1H), 3.39 (s, 3H), 3.33–3.23 (m, 3H), 3.13–2.99 (m, 2H), 2.94 (s, 7H), 2.63 (t, J = 10.2 Hz, 
1H), 2.34 (t, J = 11.7 Hz, 1H), 1.98–1.82 (m, 3H), 1.64 (bs, 2H), 1.54–1.45 (m, 3H), 1.36 (bs, 4H), 
1.30–1.24 (m, 1H), 0.76 (t, J = 10.8 Hz, 1H); 13C NMR (1:1 MeOD:D2O) δCH 174.0, 146.7, 139.4, 
130.9, 124.9, 121.5, 119.1, 90.3, 77.4, 64.1, 51.8, 47.3, 44.8, 43.0, 42.8, 40.4, 40.2, 36.7, 32.5, 30.53, 
29.4, 29.2, 27.8, 26.6, 26.4, 25.0, 19.5. HRMS (ESI-TOF) m/z C27H39N3O4 [MH]
+ calcd, 470.3013; 
found, 470.3011. 
(3R,4aS,7R,7aR,12bS)-6-((6-ammoniohexyl)carbamoyl)-9-hydroxy-7-methoxy-3-methyl-
1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium 2,2,2-
trifluoroacetate (11b) 
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Compound 10 (181 mg, 0.317 mmol) was added to a 1:1 solution of water and trifluoroacetic acid (2 
mL) and left to stir at room temperature for 6 hours.  The resulting solution was lyophilized and the 
solid purified by reverse-phase prep HPLC (5–100% buffer D in C) to give compound 11b as a white 
solid (76 mg, 34%).  1H NMR (MeOD) δHH 6.74 (d, J = 8.1 Hz, 1H), 6.66 (d, J = 8.1 Hz, 1H), 4.60 (d, J = 1.9 
Hz, 1H), 3.69 (d, J = 6.8 Hz, 1H), 3.42 (s, 3H), 3.37–3.32 (m, 2H), 3.30–3.25 (m, 1H), 3.14–3.07 (m, 2H), 2.99–
2.88 (m, 6H), 2.81–2.73 (m, 1H), 2.63–2.52 (m, 1H), 2.33 (td, J = 14.1, 5.3 Hz, 1H), 2.11–1.81 (m, 3H), 1.73–
1.60 (m, 2H), 1.56–1.49 (m, 3H), 1.45–1.37 (m, 5H), 0.86–0.80 (m, 1H). 19F NMR (MeOD) δ -76.8, 77.4.   
 tert-Butyl(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl)carbamate (12).  Compound 3 (536 
mg, 2.48 mmol) was added to THF (9 mL) and sat. NaHCO3 (15 mL) and left to stir at 0 
oC for 10 min.  
N-(Ethoxycarbonyl)maleimide (386 mg, 2.28 mmol) dissolved in more THF (6 mL) and then slowly 
added over 5 min.  The mixture was allowed to stir for 15 min, after which time a further 30 mL of 
THF was added.  This mixture was allowed to stir for another 45 min and cool to room temperature.  
The mixture was then extracted with EtOAc (3 × 60 mL), washed with brine (120 mL), dried with 
Na2SO4 and the solvent removed in vacuo.  The residual solid was purified by column chromatography 
(EtOAc) to yield compound 12 as a white solid (89%, 602 mg).  1H NMR and 13C NMR spectral data 
were in agreement with Kobayashi et al.68 
 tert-Butyl (6-((1R,4aS,9aR,10R,10aS,13aR)-8-hydroxy-10-methoxy-2-methyl-11,13-dioxo-
1,2,3,4,9a,10,10a,11,13,13a-decahydro-12H-10,13b-etheno-1,5-methanobenzofuro[3,2-e]pyrrolo[3,4-
h]isoquinolin-12-yl)hexyl)carbamate (13).  Oripavine (244 mg, 0.819 mmol) and compound 12 (276 
mg, 0.933 mmol) were added to ethanol (10 mL) and refluxed for 5 h.  The solvent was removed in 
vacuo and the residual black oil purified by column chromatography (0–2% MeOH in CHCl3).  The 
relevant fractions were combined and the solvent evaporated in vacuo to give compound 13 as an off-
white solid (52%, 255 mg).  1H NMR (CDCl3) δHH 6.61 (d, J = 8.1 Hz, 1H), 6.47 (d, J = 8.1 Hz, 1H), 
5.65 (d, J = 8.7 Hz, 1H), 5.32 (d, J = 8.8 Hz, 1H), 4.62 (d, J = 1.1 Hz, 1H), 4.59 (t, J = 5.7 Hz, 1H), 
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4.17 (d, J = 7.9 Hz, 1H), 3.97 (d, J = 6.6 Hz, 1H), 3.66 (s, 3H), 3.35 (t, J = 7.1 Hz, 2H), 3.20 (d, J = 
18.7 Hz, 1H), 3.08–2.96 (m, 3H), 2.59–2.52 (m, 1H), 2.49–2.33 (m, 5H), 1.99–1.78 (m, 2H), 1.46–1.32 
(m, 13H), 1.26–1.12 (m, 4H); 13C NMR (CDCl3) δCH 177.5, 174.3, 156.1, 146.6, 138.2, 133.7, 132.6, 
128.6, 127.0, 120.4, 117.3, 90.6, 80.8, 79.2, 57.1, 51.5, 48.1, 45.2, 45.2, 43.3, 42.2, 41.2, 40.4, 38.8, 
33.4, 29.8, 28.5, 27.5, 26.3, 26.1, 22.6.  HRMS (ESI-TOF) m/z C33H43N3O7 [MH]
+ calcd, 494.2649; 
found, 494.2668. 
 (1R,2S,4aS,9aR,10R,10aS,13aR)-12-(6-Ammoniohexyl)-8-hydroxy-10-methoxy-2-methyl-11,13-
dioxo-1,2,3,4,9a,10,10a,12,13,13a-decahydro-11H-10,13b-etheno-1,5-methanobenzofuro[3,2-
e]pyrrolo[3,4-h]isoquinolin-2-ium chloride (14).  Compound 13 (203 mg, 0.343 mmol) was stirred in 4 
M HCl in dioxane (5 mL) for 1 h at room temperature. The reaction mixture was then neutralized with 
sat. NaHCO3 and the solvent removed in vacuo.  The residue was purified by column chromatography 
(84:10:1 CHCl3:MeOH:NH4OH) and the relevant fractions evaporated under reduced pressure.  The 
remaining oil was dissolved in 1 M HCl (10 mL) and lyophilized to give compound 14 (bis-HCl salt) 
as a pale orange solid (167 mg, 86 1H NMR (DMSO) δHH 6.46 (d, J = 8.0 Hz, 1H), 6.40 (d, J = 8.1 Hz, 
1H), 5.47 (d, J = 8.7 Hz, 1H), 5.34 (d, J = 8.7 Hz, 1H), 4.76 (s, 1H), 4.11 (d, J = 7.8 Hz, 1H), 3.81 (d, J 
= 6.5 Hz, 1H), 3.53 (s, 3H), 3.40 (d, J = 7.9 Hz, 1H), 3.24 (t, J = 6.8 Hz, 2H), 3.09 (d, J = 18.5 Hz, 1H), 
2.53–2.43 (m, 4H), 2.37–2.22 (m, 4H), 2.11–1.96 (m, 1H), 1.70 (d, J = 11.3 Hz, 1H), 1.42–0.97 (m, 
8H); 13C NMR (d6-DMSO) δCH 177.4, 174.2, 146.5, 138.6, 133.5, 132.7, 128.7, 125.7, 119.6, 116.8, 
88.2, 80.5, 56.6, 50.4, 47.2, 44.7, 44.6, 43.0, 42.1, 41.3, 40.4, 37.7, 32.8, 32.5, 27.1, 26.0, 25.9, 21.7.  
HRMS (ESI-TOF) m/z C28H35N3O5 [MH]
+ calcd, 494.2649; found, 494.2668. 
 3-(4-Hydroxybutoxy)-6-methoxy-s-tetrazine (17).  1,4-Butanediol (725 µL, 8.16 mmol) was 
slowly added to a stirred mixture of 60% NaH (270 mg, 6.75 mmol) in anhydrous THF (50 mL).  The 
mixture was allowed to stir under an N2 atmosphere for 30 min.  3-Chloro-6-methoxy-s-tetrazine (795 
mg, 5.44 mmol) was dissolved in anhydrous THF (20 mL) in a separate flask.  Both of the 
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aforementioned mixtures/solutions were cooled to -78 oC.  The solution containing the 3-chloro-6-
methoxy-s-tetrazine was quickly poured into the alkoxide mixture.  The resulting mixture was kept at -
78 oC for 1 h, then allowed to warm slowly to room temperature and stirred for a further 30 min.  The 
mixture was filtered and the retentate washed with dichloromethane.  The filtrate was concentrated in 
vacuo and purified by column chromatography (100% CHCl3) to give 18 as a red solid (211 mg, 19%). 
1H NMR and 13C NMR spectral data were in agreement with Gong et al.52 
 4-((6-Methoxy-1,2,4,5-tetrazin-3-yl)oxy)butanoic acid (18).  To a stirred solution of 17 (222 mg, 
1.11 mmol) in ACN (10 ml) at 0 oC was added a solution of CrO3 (1.52 mg, 15.2 µmol) and H5IO6 (650 
mg, 2.85 mmol) in ACN (14 mL). The reaction mixture was stirred at 0 oC for 30 min, then warmed to 
room temperature and stirred for further 30 min.  The solvent was then removed in vacuo and the 
residue taken up in EtOAc (50 mL), washed with half-saturated brine (30 mL), sodium bisulfite 
solution (1 g NaHSO3 in 20 mL H2O) and brine again (30 mL), before being dried with Na2SO4 and the 
solvent removed in vacuo to give 18 as a pink solid (238 mg, 100%). 1H NMR (MeOD) δHH 4.61 (t, J = 
6.3 Hz, 2H), 4.21 (s, 3H), 2.55 (t, J = 7.3 Hz, 2H), 2.23–2.15 (m, 2H); 13C NMR (MeOD) δCH 176.7, 
167.9, 167.6, 69.9, 57.1, 31.2, 25.3.  
 2,5-Dioxopyrrolidin-1-yl 4-((6-methoxy-1,2,4,5-tetrazin-3-yl)oxy)butanoate (19).  To a stirred 
solution of 18 (64.4 mg, 0.301 mmol) in dry DCM (3 mL) at 0 oC was added N-hydroxysuccinimide 
(42.5 mg, 0.369 mmol) and dicyclohexylcarbodiimide (89.7 mg, 0.435 mmol).  The reaction mixture 
was stirred at 0 oC for 30 min, warmed to room temperature and stirred for a further 30 min, then 
placed in the freezer at -20 oC for 2 h.  The mixture was then filtered, the collected precipitate washed 
with minimal cold DCM, and the filtrate concentrated to dryness in vacuo.  The residue was purified 
via column chromatography (1:99 (v/v) MeOH:DCM) to give 19 as an impure pink oil (91 mg, 97% 
recovery (75% 19, 25% DCU by mass according to 1H NMR). 1H NMR (MeOD) δHH 4.66 (t, J = 6.1 
Hz, 2H), 4.22 (s, 3H), 2.93 (t, J = 7.2 Hz, 2H), 2.83 (s, 4H), 2.33 (app, J = 6.6 Hz, 2H). 
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  Pharmacology.  Cell lines and transfection.  FlpIn Chinese hamster ovary (CHO) cells 
(Invitrogen, Carlsbad, USA) were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 5% fetal bovine serum and maintained at 37 °C in a humidified incubator 
containing 5% CO2. The FlpIn CHO cells were transfected with the pOG44 vector encoding Flp 
recombinase and the pDEST vector containing the full coding sequence for the human mu-, delta- or 
kappa opioid receptors (hMOR, hDOR and hKOR, respectively) at a ratio of 9:1 using 
polyethylenimine as transfection reagent.  At 24 h-post transfection the cells were subcultured and the 
medium was supplemented with 700 μg mL-1 Hygromycin as selection agent. Cells were grown and 
maintained in DMEM containing 20 mM HEPES, 5% fetal bovine serum and 200 μg mL-1 
Hygromycin-B at 37 °C in a humidified incubator containing 5% CO2. 
 HEK 293 cells (ATCC, Middlesex, UK) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum and maintained at 37 °C in a humidified 
incubator containing 5% CO2. The HEK 293 cells were transfected with the pcDNA3.1+ vector 
containing the full coding sequence for the human MOR (hMOR) or the hMOR-GFP fusion protein 
using Lipofectamine as transfection reagent according to manufacturer’s instructions. 24 h post 
transfection the cells were subcultured and the medium was supplemented with 1 μg mL-1 G418 as 
selection agent. Cells were grown and maintained in DMEM containing, 10% fetal bovine serum and 
100 μg mL-1 G418at 37 °C in a humidified incubator containing 5% CO2. 
 Preparation of FlpIN CHO cell membranes.  Cells were harvested and centrifuged (300 x g, 3 
min). The resulting pellet was resuspended in assay buffer (20 mM HEPES, 100 mM NaCl, 6 mM 
MgCl2, 1 mM EGTA, 1 mM EDTA; pH 7.4), and the centrifugation procedure was repeated. The intact 
cell pellet was then resuspended in assay buffer and homogenized using a Polytron homogeniser for 
three 10-sec intervals on the maximum setting, with 30-sec periods on ice between each burst. The 
homogenate was made up to 30 mL and centrifuged (1,000 g, 10 min, 25 °C), the pellet discarded and 
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the supernatant centrifuged at 30,000 g for 1 h at 4 °C. The resulting pellet was resuspended in 5 mL 
assay buffer and the protein content determined. The homogenate was then separated into 1 mL 
aliquots and stored frozen at -80 °C until required for binding assays. 
 [3H]Diphrenorphine binding assay.   Cell membranes (20 μg) were incubated with varying 
concentrations of test compound in binding   buffer (50 mM Tris, 100 mM NaCl, 3 mM MgCl2; pH 
7.4) containing 0.3 nM of [3H]diprenorphine (Perkin Elmer) and 100 μM GppNHp to a final volume of 
0.5 mL and incubated at 25 °C for 1 h. Non-specific binding was determined in the presence of 100 µM 
naloxone. Binding was terminated by fast flow filtration over GF/B membranes using a Brandel 
harvester followed by three washes with ice cold 0.9% NaCl. Bound radioactivity was measured in a 
Tri-Carb 2900TR liquid scintillation counter (Perkin Elmer). 
 ERK1/2 phosphorylation assay.  FlpIn CHO cells stably expressing the three different OR 
subtypes were seeded into 96-well plates at a density of 40,000 cells well-1. After 5–7 h, cells were 
washed with phosphate-buffered saline (PBS) and incubated in serum-free DMEM overnight before 
assaying. Initially, time-course experiments were conducted at least twice for each ligand to determine 
their agonist activity and the time required to maximally promote ERK1/2 phosphorylation. Antagonist 
concentration-response curves were generated by preincubating the cells with increasing concentrations 
of each compound for 30 min at 37 °C and stimulating the cells with an EC50 concentration of agonist 
(DAMGO for MOR, SNC-80 for DOR and ICI199441 for KOR) for 5 min at 37 °C. Stimulation of the 
cells was terminated by removing the media and the addition of 100 μL of SureFire lysis buffer 
(PerkinElmer, Waltham, USA) to each well. The plate was shaken for 5 min at RT before transferring 5 
μL of the lysates to a white 384-well Proxiplate (PerkinElmer, Waltham, USA). 8 μL of a 240:1440:7:7 
mixture of Surefire activation buffer/Surefire reaction buffer/Alphascreen acceptor beads /Alphascreen 
donor beads was then added to the samples, before incubation in the dark at 37 °C for 1.5 h. Plates 
were read using a Fusion-TM plate reader (PerkinElmer, Waltham, USA). Antagonist concentration-
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response curves were fitted to a Gaddum-Schild equation to describe competitive antagonism.59  
Imaging Studies.  HEK cells stably expressing a C-terminal tagged human MOR (HEK-MOR-GFP 
cells) were grown on Nunc Labtek 8 well plates in DMEM + 10% fetal calf serum (FCS) + 2 mM 
glutamine. Cells were incubated in HEPES-buffered saline solution (HBSS)8 for 30 min at 37 oC in the 
presence or absence of naloxone (1 µM) prior to addition of the fluorescent ligand at the indicated 
concentrations for 30 min at 37 oC. 
 Single-time point confocal images for HEK-MOR-GFP cells incubated with 2 and 3 were 
captured using on a Zeiss LSM Exciter or Zeiss LSM710 confocal microscope using a Plan-
Apochromat 63x 1.3NA oil-immersion objective lens. Samples were excited using a 633 nm HeNe 
laser and an HFT458/543/633 dichroic with emission collected through a 650LP filter, with the 
emission pinhole set at 123 µm.  GFP fluorescence was captured using a 488 nm Argon laser and 505-
530BP filter with the same pinhole size to give an equivalent slice depth.  Attempts were made to 
image cells incubated with 1 and 4 using the same setup, but with a 405 nm diode laser, an MBS plate 
beam splitter and the emission pinhole set at 81 µm.  All images comparative were obtained on the 
same day using the same microscope settings for laser power, offset and gain. 
 High-content analysis was carried out on an IX (ImageXpress) Ultra automated confocal plate 
reader (Molecular Devices, Sunnyvale, US). HEK-MOR cells were grown to confluency in 96-well 
plates over two days in DMEM + 10% FCS, then simultaneously incubated (30 min, 37 oC) in HBSS 
with increasing concentrations of unlabelled compounds and 50 nM of 3 and four images per well 
captured (633 nm excitation, 650LP emission filter).  The average total fluorescence intensity over the 
four images was determined using MetaXpress software (Molecular Devices LLC, Sunnyvale, CA).  
For the time course experiments, 2 and 3 were incubated at 37 oC for 5, 10, 15, 20 and 30 min at 100 
nM and 10 nM, respectively, with and without coincubation of naloxone (1 µM).  Half of the wells 
were washed once with HBSS prior to imaging. 
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Competition curves were constructed using GraphPad Prism 6 by plotting the loss of fluorescence 
intensity as a function of competitive ligand concentration using the Cheng-Prusoff equation and the A2 
value for 3 (49 nM).  All graphs represent the average of normalized measurements taken from three 
individual experiments performed in duplicate. 
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 ABBREVIATIONS USED 
Boc, butyloxycarbonyl; BODIPYTM, boron dipyrromethene difluoride; cAMP, cyclic adenosine 
monophosphate; CHO, chinese hamster ovary; cns, central nervous system; Cy5, cyanine five; d, 
doublet; DAMGO, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DCM, dichloromethane; DCT, 
dichlorotetrazine; DIPEA, N,N-diisopropylethylamine; DMF, N,N-dimethylformamide; DMSO, 
dimethylsulfoxide; DOR, delta opioid receptor; EDC.HCl, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride; ELISA, enzyme linked-immunosorbent assay; ESI 
electrospray ionization; FCS, fetal calf serum; FRET, fluorescence resonance energy transfer; GDP, 
guanosine diphosphate; GFP, green fluorescent protein; GPCR, G protein-coupled receptor; GTP, 
guanosine triphosphate; HBSS, HEPES buffered saline solution; HCTU, 2-(6-chloro-1H-benzotriazole-
1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate; HOBt, N-hydroxybenzotriazole; IX, 
ImageXpress; KOR, kappa opioid receptor; MOR, mu opioid receptor; OR, opioid receptor; NHS, N-
hydroxysuccinimide; NO, Nitric Oxide; NOP, nociceptin opioid receptor; ppm, parts per million; 
PyBOP, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate; ORs, opioid receptors; 
SAR, structure-activity relationship; TBS, tert-butyldimethylsilyl; TFA, trifluoroacetic acid; THF, 
tetrahydrofuran; TICA, trichloroisocyanuric acid; XAC, xanthine amine congener; W, microwave. 
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